SCHEMBL3014169

SCHEMBL3014169

COc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Br)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
HSD17B10 Q99714 2/20 0.48
RECQL P46063 2/20 0.48
USP2 O75604 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 5/20 0.45
LMNA P02545 4/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
ALOX15 P16050 2/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
GBA1 P04062 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
THRB P10828 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014362 0.93 MAPT (0.43) MAPTHSD17B10RECQLUSP2SMN1; SMN2
SCHEMBL3006270 0.90 MAPT (0.51) MAPTHSD17B10RECQLUSP2SMN1; SMN2
SCHEMBL3014108 0.90 MAPT (0.49) MAPTHSD17B10RECQLUSP2SMN1; SMN2
SCHEMBL3003907 0.90 ALDH1A1 (0.45) MAPTHSD17B10RECQLUSP2SMN1; SMN2
SCHEMBL3016720 0.88 MAPT (0.42) MAPTHSD17B10RECQLUSP2SMN1; SMN2
SCHEMBL3012745 0.88 LMNA (0.43) MAPTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3014994 0.88 ALDH1A1 (0.42) HSD17B10RECQLUSP2ALDH1A1LMNA
SCHEMBL3018039 0.88 MAPT (0.48) MAPTHSD17B10RECQLUSP2SMN1; SMN2
SCHEMBL3006869 0.87 ALDH1A1 (0.49) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3014987 0.87 PKM (0.48) MAPTHSD17B10RECQLUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.